Rochester, NY – Rochester Clinical Research (RCR), an Atlas Clinical Research Site, is excited to announce the expansion of its clinical research network with a new site set to open in Buffalo, NY. The new site, RCR Buffalo, is set to commence operations in April of this year, marking a significant milestone in RCR’s mission to advance medical research and patient care.  “We are proud to bring RCR’s 30 year legacy of innovation and trusted clinical trials to Buffalo,” said Kelley Powers, Head of Site at RCR. “We are dedicated to creating a diverse and inclusive space where every Buffalo c ..read more

RCR announces partnership with a local non-profit called Rochester Hope [Rochester, New York] — Rochester Clinical Research (RCR) has announced its partnership with Rochester Hope, a non-profit organization dedicated to providing vital services and support to the local community. This collaboration represents a powerful commitment to making a positive impact on the lives of Rochester residents and addressing pressing community needs. In response to the evolving needs of our community, Rochester Hope came into existence in early 2021. Facing financial challenges that threatened the closure of S ..read more

In the ongoing battle against infectious diseases, one thing is for certain: a strong immune system is your best defense. Now, imagine a world where you can bolster your defenses against both COVID-19 and the flu with a single shot. Well, that world might be closer than you think. A Dual Defense Strategy As healthcare professionals and scientists continue to explore new ways to keep us safe, Rochester Clinical Research (RCR) is pleased to introduce a groundbreaking clinical trial. This new trial aims to evaluate the safety and effectiveness of a dual-action vaccine that targets both influenza ..read more

Rochester Clinical Research takes pride in its involvement in a phase 3 smoking cessation study, which has yielded promising and effective results in participants. The study aimed to assess the efficacy of Cytisinicline, a natural alkaloid present in various plant species that mimics nicotine’s effects in the brain, in promoting nicotine abstinence. Cytisinicline aids in diminishing nicotine cravings and withdrawal symptoms, easing the process of smoking cessation for individuals.    The study duration ranged from 6 to 12 weeks, depending on the dosage administered to each parti ..read more

FOR IMMEDIATE RELEASE Rochester Clinical Research (RCR) Supports the Rochester Puerto Rican Festival, Offers Ticket Giveaway Enter for a chance to win free tickets to Rochester’s 53rd Annual Puerto Rican Festival ROCHESTER, NY – Rochester Clinical Research (RCR) is excited to announce its sponsorship and participation in the highly-anticipated Rochester Puerto Rican Festival, taking place from August 3 – 5 at Innovation Field.  The festival, running from 5 – 11 p.m. on Thursday and Friday and from 12 – 5 p.m. on Saturday, promises attendees a vibrant mix of live music, food, and cultural ..read more

Clinic staff to volunteer at four-day “Welcoming the Stranger” fundraiser helping thousands of Rochester-area refugees Rochester Clinical Research (RCR) proudly announces its collaboration with Saints’ Place in organizing a remarkable Super Sale event aimed at benefiting area refugees, including hundreds of Ukranians displaced by war. As part of their ongoing commitment to the Rochester community and fostering goodwill, RCR has volunteered to contribute to this important fundraising event. More details about the Super Sale. “Many refugees arrive in Rochester with little more than the clothes ..read more

Popular local drag performer will speak about diversity and inclusion at a special Pride event on Thursday June 29th. Rochester Clinical Research (RCR), announced that Mrs. Kasha Davis, a popular drag queen, actor and television personality is scheduled to speak at the “RCR Allyship Lunch & Learn” on Thursday June 29th, from 12pm-1pm. Davis is best known for competing on the seventh season of RuPaul’s Drag Race. A powerful voice in the LGBTQ+ community, she will be addressing the crucial significance of diversity and inclusion. The event is a staff event sponsored by the DEI Council at RC ..read more

Rochester Clinical Research takes great pride in its contribution to Pfizer’s groundbreaking study on Zavzpret (zavegepant) migraine nasal spray, which has recently received FDA approval. This innovative treatment is the first of its kind designed to treat acute migraines in adults by acting as a calcitonin gene-related peptide (CGRP) receptor antagonist, effectively inhibiting CGRP from causing migraine attacks. With over 40 million Americans suffering from migraines, this development is nothing short of a medical triumph. Zavzpret offers a compelling alternative to oral medication, which can ..read more

Doctors working to develop a vaccine for Lyme Disease Patrick Moussignac News10NBC April 26, 2023 – 5:56 PM ROCHESTER, N.Y. – Lyme disease is one of the most common diseases transmitted by an insect bite. Doctors say it’s prevalent here in western New York, and no one is immune. There are also no vaccines for it.   Rochester Clinical Research is trying to change that.  Clinical trials are underway to help develop a Lyme disease vaccine for children.  As the weather warms, we spend more time outside. The tick population continues to grow. One of them could be carrying t ..read more

Simultaneously forms strategic partnership with Rochester Clinical Research, marking the foundational clinical research site of the new platform CHICAGO, April 12, 2023 /PRNewswire/ — BPOC, a pure-play healthcare investor with over 25 years of experience in middle market private equity, today announced the launch of Atlas Clinical Research (“Atlas”), a therapeutically-driven clinical site network built on centralized process excellence and integrated technology, led by experienced pharmaceutical executive, Mark Scullion as Chief Executive Officer. As part of the launch ..read more